Cancer cells impair monocyte-mediated T-cell activation by disrupting inflammatory pathways in the tumor microenvironment.

A study from the University of Michigan Health Rogel Cancer Center may have—at last—cracked the cold case of immunotherapy ...

Recent advances in immunotherapy research have revealed crucial roles for new immune cells in combating cancer, leading to ...

Prostate cancer and other cancers characterized by “cold” tumors could become more responsive to checkpoint blockade if UBA1 is inhibited.

Study uses spatial transcriptomics to map intratumoral heterogeneity and microenvironmental dynamics in triple-negative ...

A recent study reveals that immunosuppression, or reduced immune response, in prostate cancer is associated with a ...

University of Michigan researchers identified UBA1 as a key player in immunotherapy resistance. Inhibiting UBA1 boosts T-cell ...

The cancer microenvironment, or tumour microenvironment, describes the non-cancerous cells present in the tumour. These include fibroblasts, immune cells and cells that comprise the blood vessels.

A study uncovers how cancer cells adapt to low-glucose environments, resisting chemotherapy by conserving uridine nucleotides ...

REHOVOT, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) -- (“Purple Biotech” or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage ...

Cancer metabolism is a critical area of research, central to understanding how malignant tumors manipulate metabolic pathways to support their growth and survival. These alterations not only fuel ...

Many cancer drugs are antimetabolites, which interfere with the cellular processes necessary for tumor growth and survival.